Accelerating Access to Critical Therapies for ALS Act
Summary
The Accelerating Access to Critical Therapies for ALS Act was signed into law in December 2021, establishing grant programs for ALS and neurodegenerative disease research. The law authorizes HHS and FDA grants for expanded access to investigational ALS treatments and R&D for drugs targeting ALS and rare neurodegenerative diseases. Biogen ($BIIB), Ionis ($IONS), AbbVie ($ABBV), and AstraZeneca ($AZN) are positioned to benefit from non-dilutive funding and accelerated patient access to their ALS pipelines.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.The ALS Act is already law, creating a permanent grant framework for ALS and neurodegenerative disease research
- 2.No specific funding amount is authorized — actual spending depends on future appropriations bills
- 3.Biogen ($BIIB) and Ionis ($IONS) have the most direct ALS pipeline exposure and are primary beneficiaries
- 4.Expanded access grants could accelerate patient enrollment and real-world data collection for investigational ALS therapies
- 5.Broad bipartisan support (331 cosponsors) increases likelihood of future appropriations
Market Implications
The ALS Act is already law, so its market impact is structural rather than event-driven. Biogen ($BIIB) is the most leveraged pure-play ALS company with an approved drug (Qalsody) and pipeline candidates. Ionis ($IONS) offers exposure to ASO technology that is central to ALS gene-targeted therapies. AbbVie ($ABBV) and AstraZeneca ($AZN) have broader neurology portfolios where ALS is a smaller component. The lack of a specific funding amount means near-term revenue impact is uncertain — the key catalyst will be future appropriations bills that allocate actual dollars to these grant programs. Investors should watch the House and Senate Appropriations Committees' HHS/FDA funding marks for ALS-specific line items.
Full Analysis
The Accelerating Access to Critical Therapies for ALS Act (H.R. 3537) was signed into law on December 23, 2021, as Public Law 117-79. This is a completed legislative action — the bill is already law, not pending. The law directs HHS to award grants for scientific research using data from expanded access to investigational ALS treatments for patients ineligible for clinical trials. Separately, the FDA must award grants to public and private entities for R&D of drugs treating ALS and other rare neurodegenerative diseases. HHS is also required to establish a Public-Private Partnership for Neurodegenerative Diseases.
The money trail: This is an authorization bill, not an appropriation. It authorizes the grant programs but does not allocate specific dollar amounts — actual funding requires subsequent appropriations bills. The law creates the legal framework for federal spending on ALS expanded access and R&D, but the exact budget depends on annual appropriations. No specific funding amount is stated in the bill text provided.
Structural winners: Biogen ($BIIB) has the most direct exposure with its approved ALS drug Qalsody (tofersen) for SOD1-ALS and a pipeline of ALS candidates. Expanded access grants could increase patient enrollment and revenue. Ionis ($IONS) is a pure-play antisense oligonucleotide (ASO) company with multiple ALS programs — grants directly support its core technology. AbbVie ($ABBV) and AstraZeneca ($AZN) have ALS pipeline assets but represent smaller portions of their diversified portfolios. The law's focus on expanded access data collection benefits companies with existing investigational ALS therapies by generating real-world evidence that could support broader approvals.
Timeline: The law is already in effect. Implementation depends on HHS and FDA rulemaking and appropriations. The 331 cosponsors (original and later) indicate broad bipartisan support, which may facilitate future appropriations. No further legislative steps remain for this bill.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Justice for ALS Veterans Act of 2025
ALS Disability Insurance Access Act of 2019
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Accelerating Access To Veterans' Benefits And Employment Opportunities
This proclamation orders the Secretaries of War and Veterans Affairs to mandate rapid, ongoing digital sharing of military personnel and medical records, deploy AI-powered tools for benefits applications, and update existing IT contracts for interoperability. It also requires the Transition Assistance Program to connect separating service members to specific jobs or training programs before discharge.
Delivering Gold Standard Childhood Vaccine Recommendations for Americans
This executive order directs HHS to establish a 'Gold Standard' childhood vaccine schedule with fewer recommended vaccines than current CDC guidelines, mandates that MMR be administered as three separate single-disease shots when domestically available, and instructs the DOJ to challenge state vaccine mandates that do not provide religious or medical exemptions. It also orders HHS to develop alternative adjuvants to aluminum and improve vaccine safety monitoring, while preserving access to existing vaccines.
Continuing to Protect the Meaning and Value of American Citizenship
This executive order directs federal agencies, including State, Justice, Homeland Security, and Social Security, to deny U.S. citizenship documentation to children born in the U.S. whose parents include alien enemies, foreign government employees, or those involved in commercial birth tourism or surrogacy, or who are born in territories without statutory citizenship. It implements a narrow interpretation of the Fourteenth Amendment following the Supreme Court's decision in Trump v. Barbara, effectively restricting birthright citizenship for specific categories of non-citizen parents.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →